Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017

Palivizumab is the only licensed respiratory syncytial virus (RSV) immunoprophylaxis (IP) available to prevent severe RSV disease in high-risk pediatric populations, including infants born at 29–34 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics (AAP) stopped recommending R...

Full description

Bibliographic Details
Main Authors: Jaime Fergie, Mitchell Goldstein, Leonard R. Krilov, Sally W. Wade, Amanda M. Kong, Lance Brannman
Format: Article
Language:English
Published: Taylor & Francis Group 2021-05-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
rsv hospitalization
rsv prevention
29-34 wga infants
high-risk infants
palivizumab
Online Access:http://dx.doi.org/10.1080/21645515.2020.1822134

Internet

http://dx.doi.org/10.1080/21645515.2020.1822134

Similar Items